HEART UK responds to Dept of Health announcement on new cholesterol drug
The cholesterol charity HEART UK responds to the Department of Health and Social Care announcement that a new cholesterol drug, inclisiran, could be made available for NHS patients through a ground-breaking collaboration.
Jules Payne, Chief Executive of the cholesterol charity HEART UK, said: “Cholesterol is a leading cause of heart disease, so effective treatments save lives.
“While we know beyond doubt that statins are incredibly effective at treating people with high cholesterol, there is a desperate need for new and innovative drugs if we are to tackle cardiovascular disease, a condition which kills hundreds of thousands of people in this country every year.
“The potential for this breakthrough new drug is incredibly exciting but we need to ensure all those eligible for it, once fully approved, will get access to it.”
For more information and interviews, please contact the HEART UK media team on 07736 469509 or email media@heartuk.org.uk
Related stories
- HEART UK launches ‘Prevention Pays’ analysis
- Study Request for Patients with high cholesterol
- Resolving the Cholesterol Controversy By Gilbert R Thompson (Imperial College London, UK)
- HEART UK response to NICE Guidance (December 2023)
- Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration*
- We are delighted to announce our Fundraising Awards for 2023.
- Evaluation of national lipid optimisation programme – Appeal for engagement
- Lipid management in Scotland: Recommendations for action
- Could you or a young person you know help shape FH (familial hypercholesterolaemia) care for the future?
- HEART UK Shortlisted for Top Award - Best Not-for-Profit Working in Partnership